Your session is about to expire
← Back to Search
Dupilumab for Ulcerative Colitis
Study Summary
This trial will evaluate the effect of dupilumab on UC symptoms, safety and effectiveness in patients with moderate-severe UC and eosinophilic phenotype.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 188 Patients • NCT04033367Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Dupilumab
- Group 2: Placebo
Frequently Asked Questions
Has Dupilumab received regulatory approval from the Federal Drug Administration?
"There is evidence that dupilumab has a moderate safety profile, thus it received an evaluation of 2."
What is the highest participant capacity for this trial?
"Affirmative. The official records on clinicaltrials.gov have indicated that this research endeavor is actively enrolling individuals. It was initially listed on December 1st 2023 and most recently updated February 15th 2023, with the aim of recruiting 100 subjects between two medical centres."
Does this research endeavor still have availability for participants?
"Affirmative. According to clinicaltrials.gov, this medical trial is actively recruiting participants; it was initially posted on December 1st 2023 and the most recent update occured on February 15th 2023. The study requires 100 volunteers from 2 locations."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Average response time
- < 2 Days
Most responsive sites:
- Smart Medical Research, Inc: < 24 hours
Share this study with friends
Copy Link
Messenger